DLX-2270

Last updated

DLX-2270
Clinical data
Other namesDLX2270
Routes of
administration 		Oral [1]
Drug class Serotonin 5-HT2A receptor antagonist; Serotonin 5-HT2C receptor agonist; Antipsychotic; Psychoplastogen [1]
ATC code
  • None

DLX-2270 is an experimental serotonin receptor modulator which is under investigation for the potential treatment of schizophrenia. [1]

It acts as a serotonin 5-HT2A receptor antagonist and serotonin 5-HT2C receptor agonist. [1] In contrast to conventional antipsychotics, DLX-2270 is not a dopamine D2 receptor antagonist. [1] The drug is orally active and centrally penetrant. [1] In preclinical research, DLX-2270 has psychoplastogenic effects. [1] It reverses hyperlocomotion and social interaction deficits induced by the NMDA receptor antagonist phencyclidine (PCP). [1] In contrast to serotonin 5-HT2A receptor agonists, DLX-2270 does not produce the head-twitch response in rodents, and hence would not be expected to be hallucinogenic in humans. [1]

DLX-2270 was first described in the scientific literature in 2025. [1] It is under development by Delix Therapeutics. [1] DLX-2270 is a small molecule, but its chemical structure does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 Leach P, Prince R, Agrawal R, Gillie D, Mungenast A, McTighe S, et al. (2025). "569. Preclinical Pharmacology of DLX-2270: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Schizophrenia" . Biological Psychiatry. 97 (9): S333. doi:10.1016/j.biopsych.2025.02.808 . Retrieved 13 May 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.